Item 1.01. Entry into a Material Definitive
Agreement.
Exclusive License Agreement
On March 4, 2021, Sorrento Therapeutics,
Inc. (the “Company”) entered into an exclusive license agreement (the “License Agreement”) with Icahn School
of Medicine at Mount Sinai (“Mount Sinai”). Pursuant to the License Agreement, among other things, Mount Sinai granted
the Company a worldwide, exclusive, sublicensable license to certain of Mount Sinai’s patents and monoclonal antibodies and
a worldwide, non-exclusive, sublicensable license to certain of Mount Sinai’s technical information to develop, manufacture,
commercialize, and exploit related products and services (“Licensed Products”) for all fields, uses, and applications,
including for the diagnosis, prevention, treatment, and cure of coronavirus.
As consideration for the license under
the License Agreement, the Company agreed to (i) enter into a stock purchase agreement to sell the Shares (as defined below) to
Mount Sinai, and (ii) pay to Mount Sinai certain milestone payments upon the achievement of certain clinical trial and regulatory
milestones.
The Company will also pay Mount Sinai royalties
in the low-single digit to mid-single digit percentages of annual net sales of Licensed Products by the Company and a share of
any sublicense revenue received by the Company from sublicensees.
The foregoing summary of the License Agreement
does not purport to be complete and is qualified in its entirety by reference to the full text of the License Agreement. A copy
of the License Agreement will be filed with the Securities and Exchange Commission (the “SEC”) as an exhibit to the
Company’s Quarterly Report on Form 10-Q for the quarter ending March 31, 2021 (the “Form 10-Q”) or via an amendment
to this Current Report on Form 8-K. Certain terms of the License Agreement have been omitted from this Current Report on Form 8-K
and will be omitted from the version of the License Agreement to be filed as an exhibit to the Form 10-Q or via an amendment to
this Current Report on Form 8-K pursuant to Item 601(b)(10) of Regulation S-K because such terms are both (i) not material and
(ii) would likely cause competitive harm to the Company if publicly disclosed.
The representations, warranties and covenants
contained in the License Agreement were made only for purposes of such agreement and as of specific dates, were solely for the
benefit of the parties to the License Agreement, and may be subject to limitations agreed upon by the contracting parties. Accordingly,
the License Agreement is incorporated herein by reference only to provide investors with information regarding the terms of the
License Agreement, and not to provide investors with any other factual information regarding the Company or its business, and should
be read in conjunction with the disclosures in the Company’s periodic reports and other filings with the SEC.
Stock Purchase Agreement
In connection with the License
Agreement, on March 4, 2021, the Company and Mount Sinai also entered into a Stock Purchase Agreement (the “Purchase
Agreement”), pursuant to which the Company agreed to sell to Mount Sinai a number of shares of its Common Stock (the
“Shares”) equal to the quotient of (a) $7.5 million divided by (b) the Price Per Share (as defined below). The
Price Per Share shall be the lower of (i) the closing price per shares of the Common Stock on the date of the Purchase
Agreement and (ii) the weighted average closing price of the Common Stock, as reported on The Nasdaq Stock Market LLC, for
the 11 consecutive trading days beginning on the fifth trading day prior to the date of the Purchase Agreement and ending on
the fifth trading day following the date of the Purchase Agreement.
The representations, warranties and covenants
contained in the Purchase Agreement were made only for purposes of such agreement and as of specific dates, were solely for the
benefit of the parties to the Purchase Agreement, and may be subject to limitations agreed upon by the contracting parties. Accordingly,
the Purchase Agreement is incorporated herein by reference only to provide investors with information regarding the terms of the
Purchase Agreement, and not to provide investors with any other factual information regarding the Company or its business, and
should be read in conjunction with the disclosures in the Company’s periodic reports and other filings with the SEC.
The foregoing summary of the Purchase Agreement
does not purport to be complete and is qualified in its entirety by reference to the full text of the Purchase Agreement, which
will be filed with the SEC as an exhibit to the Form 10-Q or via an amendment to this Current Report on Form 8-K.
Registration Rights Agreement
In connection with the License Agreement,
on March 4, 2021, the Company and Mount Sinai also entered into a Registration Rights Agreement (the “Registration Rights
Agreement”), pursuant to which the Company agreed to file and keep effective one or more registration statements (the “Registration
Statements”) with the SEC under the Securities Act of 1933, as amended, relating to the resale by Mount Sinai of the Shares.
Under the Registration Rights Agreement, the Company is required to file such Registration Statements with the SEC within 60 days
following the date on which the Shares are issued to Mount Sinai.
The foregoing summary of the Registration
Rights Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Registration
Rights Agreement, which will be filed with the SEC as an exhibit to the Form 10-Q or via an amendment to this Current Report on
Form 8-K.